Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10852
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ulus, R. | - |
dc.contributor.author | Esirden, İ. | - |
dc.contributor.author | Aday, B. | - |
dc.contributor.author | Turgut, Gurbet Çelik | - |
dc.contributor.author | Şen, A. | - |
dc.contributor.author | Kaya, M. | - |
dc.date.accessioned | 2019-08-16T13:33:26Z | |
dc.date.available | 2019-08-16T13:33:26Z | |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1054-2523 | - |
dc.identifier.uri | https://hdl.handle.net/11499/10852 | - |
dc.identifier.uri | https://doi.org/10.1007/s00044-017-2088-2 | - |
dc.description.abstract | In this study we report that amino acridine intermediates 7 and 8 were obtained from the reduction of nitro acridine derivatives 5 and 6 that were synthesized via the condensation of dimedone, p-nitrobenzaldehyde with various amine derivatives, respectively. Then acridine sulfonamide hybrid compounds (9–18) were synthesized by the reaction of amino acridine 7, 8 with sulfonyl chlorides. The new hybrid compounds were characterized by FT-IR, 1H-NMR, 13C-NMR, and HRMS analyzes. The evaluation of in vitro anticholinesterase action of the synthesized compounds against AChE showed that some of them are potent inhibitors. Among them, compound 17 showed the most potent activity against AChE with an IC50 of 0.14 µM. © 2017, Springer Science+Business Media, LLC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Birkhauser Boston | en_US |
dc.relation.ispartof | Medicinal Chemistry Research | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Acridine | en_US |
dc.subject | Anticholinesterase activity | en_US |
dc.subject | Sulfonamide | en_US |
dc.subject | Tacrine | en_US |
dc.subject | 10 (4 bromophenyl) 3,3,6,6 tetramethyl 9 (4 nitrophenyl) 3,4,6,7,9,10 hexahydro acridine 1,8(2h,5h) dione | en_US |
dc.subject | 10 (4 chlorophenyl) 3,3,6,6 tetramethyl 9 (4 nitrophenyl) 3,4,6,7,9,10 hexahydro acridine 1,8(2h,5h) dione | en_US |
dc.subject | 4 bromo n [4 [10 (4 bromophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl]benzenesulfonamide | en_US |
dc.subject | 4 bromo n [4 [10 (4 chlorophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl]benzenesulfonamide | en_US |
dc.subject | 9 (4 aminophenyl) 10 (4 bromophenyl) 3,3,6,6 tetramethyl 3,4,6,7,9,10 hexahydro acridine 1,8(2h,5h) dione | en_US |
dc.subject | 9 (4 aminophenyl) 10 (4 chlorophenyl) 3,3,6,6 tetramethyl 3,4,6,7,9,10 hexahydro acridine 1,8(2h,5h) dione | en_US |
dc.subject | acetylcholinesterase | en_US |
dc.subject | acridine derivative | en_US |
dc.subject | cholinesterase inhibitor | en_US |
dc.subject | n [4 [10 (4 bromophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl] 2,4,6 trimethylbenzenesulfonamide | en_US |
dc.subject | n [4 [10 (4 bromophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl]benzenesulfonamide | en_US |
dc.subject | n [4 [10 (4 bromophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl]naphthalene 2 sulfonamide | en_US |
dc.subject | n [4 [10 (4 chlorophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl] 2,4,6 trimethylbenzenesulfonamide | en_US |
dc.subject | n [4 [10 (4 chlorophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl] 4 methoxybenzenesulfonamide | en_US |
dc.subject | n [4 [10 (4 chlorophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl] 4 methylbenzenesulfonamide | en_US |
dc.subject | n [4 [10 (4 chlorophenyl) 3,3,6,6 tetramethyl 1,8 dioxo 1,2,3,4,5,6,7,8,9,10 decahydro acridin 9 yl]phenyl]benzenesulfonamide | en_US |
dc.subject | sulfonamide | en_US |
dc.subject | tacrine | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | Alzheimer disease | en_US |
dc.subject | Article | en_US |
dc.subject | carbon nuclear magnetic resonance | en_US |
dc.subject | cholinesterase inhibition | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | enzyme activity | en_US |
dc.subject | human | en_US |
dc.subject | human cell | en_US |
dc.subject | IC50 | en_US |
dc.subject | in vitro study | en_US |
dc.subject | infrared spectroscopy | en_US |
dc.subject | mass spectrometry | en_US |
dc.subject | proton nuclear magnetic resonance | en_US |
dc.subject | SH-SY5Y cell line | en_US |
dc.title | Synthesis of novel acridine-sulfonamide hybrid compounds as acetylcholinesterase inhibitor for the treatment of alzheimer’s disease | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 27 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 634 | |
dc.identifier.startpage | 634 | en_US |
dc.identifier.endpage | 641 | en_US |
dc.identifier.doi | 10.1007/s00044-017-2088-2 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopus | 2-s2.0-85031397121 | en_US |
dc.identifier.wos | WOS:000424646600026 | en_US |
dc.identifier.scopusquality | Q2 | - |
dc.owner | Pamukkale University | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | 17.02. Biology | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Uygulamalı Bilimler Yüksekokulu Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
16
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
15
checked on Nov 15, 2024
Page view(s)
48
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.